Glycoprotein News and Research

RSS

Study identifies key features in SARS-CoV-2 genome essential for replication in respiratory cells

Researchers at the Institute of Medical Virology, the University of Zurich in Switzerland, have identified features in the SARS-CoV-2 genome that are important for human respiratory cell growth.

29 Mar 2021

Selecting SARS-CoV-2 inhibitors in human airway epithelial cells

In a recent article currently available on the bioRxiv* preprint server, researchers from Belgium and the U.S. demonstrated a robust replication model for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) isolates in primary human epithelial cells at the air-liquid interface and appraised the antiviral effect of selected viral replication inhibitors.

28 Mar 2021

Fluoxetine (Prozac) performs strongly in vitro against SARS-CoV-2 (including mutants)

Researchers from Finland, to expand on these studies, tested some of these drugs against the new SARS-CoV-2 variants. The study is published on the preprint server bioRxiv.

24 Mar 2021

Study shows single dose of mRNA vaccine may suffice for those with prior SARS-CoV-2 infection

A recent study by researchers from Philadelphia, currently available on the medRxiv preprint server, shows that individuals with prior infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit substantial immune memory and develop a robust response to the first dose of an mRNA vaccine.

23 Mar 2021

Computational analysis reveals why new SARS-CoV-2 variants bind better to human cells

All viruses mutate as they make copies of themselves to spread and thrive. SARS-CoV-2, the virus the causes COVID-19, is proving to be no different. There are currently more than 4,000 variants of COVID-19, which has already killed more than 2.7 million people worldwide during the pandemic.

23 Mar 2021

Ai helps identify critical interactions for SARS-CoV-2 spike protein binding to ACE2

Recently, researchers from the US employed multiple-µs molecular dynamic simulations to compare the relative dynamics, stabilities, and energy differences between the SARS-CoV receptor-binding domain (RBD)-ACE2 and SARS-CoV-2 RBD-ACE2 complexes. The study is published on the preprint server, bioRxiv.

23 Mar 2021

Could nanoparticle vaccines offer broad protection against sarbecoviruses?

To understand the ability of SARS-CoV-2 vaccine-elicited antibodies to neutralize and protect against emerging variants (that are pathogenic) and other sarbecoviruses, a large team of researchers studied immunity by receptor-binding domain nanoparticle vaccines. They showed that a clinical-stage multivalent SARS-CoV-2 receptor-binding domain nanoparticle vaccine (SARS-CoV-2 RBD-NP) protected mice from the SARS-CoV-2-induced disease.

22 Mar 2021

ChAdOx1 nCoV-19 offers less protection against South African SARS-CoV-2 variant

The results of a double-blind, randomized, multisite placebo-controlled trial that was conducted in South Africa show that Oxford’s ChAdOx1 nCoV-19 (AZD1222) vaccine has no efficacy against the B.1.351 variant in preventing mild-to-moderate coronavirus disease 2019 (COVID-19), and shows reduced neutralization properties of developed antibodies. The findings are published in the New England Journal of Medicine.

21 Mar 2021

Study explores how SARS-CoV-2 mutations produce antibody resistance and enhanced transmissibility

An interesting new study deals with the effects of the natural mutations in the spike antigen of the SARS-CoV-2, the pathogen that is responsible for the ongoing coronavirus disease pandemic.

16 Mar 2021

UAB researchers find potential new pathway to treating radiation-resistant glioblastoma

Researchers at the University of Alabama at Birmingham have identified a potential new pathway to treating radiation-resistant glioblastoma, one of the most aggressive forms of brain cancer.

15 Mar 2021

Dual-action monoclonal antibodies from an original SARS survivor show promise against COVID-19

A recent study, currently available on the bioRxiv preprint server, indicates that a pair of dual-action monoclonal antibodies derived from an original 2003 SARS survivors could play an important role in the fight against coronavirus disease 2019 (COVID-19) due to their broadly neutralizing activity and the engagement of the immune system via effector function capabilities.

14 Mar 2021

Study identifies three novel binding receptors for SARS-CoV-2

A team of scientists from the United Kingdom recently conducted a large-scale screening of several membrane-bound and soluble host cell receptors to identify novel binding partners for SARS-CoV-2. They have identified three novel receptors expressed on the human cell membrane; of which, one binds to SARS-CoV-2 spike with similar affinity as angiotensin-converting enzyme 2 (ACE2).

12 Mar 2021

Natural virus-induced immunity protective against UK and South African SARS-CoV-2 variants in hamster study

As new variants of SARS-CoV-2 continue to emerge, fueling the continued spread of the COVID-19 pandemic, a new study offers encouragement.

12 Mar 2021

N501Y mutation in SARS-CoV-2 responsible for increased viral transmission

Researchers at the University of Texas, USA, have confirmed the specific mutation in the B.1.1.7 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has allowed for it to be more transmissible than the ancestral strain. The N501Y substitution is one of 8 spike protein substitutions present in the UK variant and has also appeared convergently in the Brazil (P.1) and South Africa (B.1.351) variants.

11 Mar 2021

SARS-CoV-2 spike S1 subunit induces hypercoagulability

The vascular complications of the condition include a range of various coagulopathies that cause bleeding and thrombocytopenia or a hypercoagulable state. A new preprint research paper posted to the medRxiv server describes the role of a fibrinogen-related protein in inducing these clinical features of COVID-19.

10 Mar 2021

Researchers discover new COVID-19 variants in three South African provinces

Variants of the coronavirus are appearing in different parts of the world, many of them spreading with alarming speed.

10 Mar 2021

Research demonstrates multivalent nanobodies overcome SARS-CoV-2 variant mutations

In a recent bioRxiv* preprint paper, researchers isolated anti-RBD nanobodies from llamas and “nanomice” (they engineered to produce VHHs cloned from alpacas, dromedaries and camels).

10 Mar 2021

Optimized SARS-CoV-2 vaccine candidate could be less reactogenic, say researchers

A new study, released as a preprint on the bioRxiv* server, reports an optimized coronavirus disease 2019 (COVID-19) vaccine candidate, which, claim the researchers, may be less likely to produce reactions like fevers. It may also have increased protective potential against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen that causes COVID-19.

9 Mar 2021

Delayed detection of oral fluid anti-SARS-CoV-2 antibodies increases the time to viral clearance

A prospective observational study has revealed that the late appearance of anti-SARS-CoV-2 antibodies in oral fluid, absence of fever as an early symptom, and elevated BMI are associated with delayed clearance of viral RNA in mild to moderate COVID-19 patients.

4 Mar 2021

Cell surface marker CD47 may allow early diagnosis of severe COVID-19

A new study reports the potential of the cell surface marker, CD47, as a biomarker for hyperinflammation, a characteristic feature of severe COVID-19.

4 Mar 2021

Glycoprotein News and Research

Study identifies key features in SARS-CoV-2 genome essential for replication in respiratory cells

Selecting SARS-CoV-2 inhibitors in human airway epithelial cells

Fluoxetine (Prozac) performs strongly in vitro against SARS-CoV-2 (including mutants)

Study shows single dose of mRNA vaccine may suffice for those with prior SARS-CoV-2 infection

Computational analysis reveals why new SARS-CoV-2 variants bind better to human cells

Ai helps identify critical interactions for SARS-CoV-2 spike protein binding to ACE2

Could nanoparticle vaccines offer broad protection against sarbecoviruses?

ChAdOx1 nCoV-19 offers less protection against South African SARS-CoV-2 variant

Study explores how SARS-CoV-2 mutations produce antibody resistance and enhanced transmissibility

UAB researchers find potential new pathway to treating radiation-resistant glioblastoma

Dual-action monoclonal antibodies from an original SARS survivor show promise against COVID-19

Study identifies three novel binding receptors for SARS-CoV-2

Natural virus-induced immunity protective against UK and South African SARS-CoV-2 variants in hamster study

N501Y mutation in SARS-CoV-2 responsible for increased viral transmission

SARS-CoV-2 spike S1 subunit induces hypercoagulability

Researchers discover new COVID-19 variants in three South African provinces

Research demonstrates multivalent nanobodies overcome SARS-CoV-2 variant mutations

Optimized SARS-CoV-2 vaccine candidate could be less reactogenic, say researchers

Delayed detection of oral fluid anti-SARS-CoV-2 antibodies increases the time to viral clearance

Cell surface marker CD47 may allow early diagnosis of severe COVID-19

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News